Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
101 to 120 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -26.2 | Standard Deviation 24.40 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -58.7 | Standard Deviation 34.81 | percent change |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -0.4 | Standard Deviation 0.50 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -0.9 | Standard Deviation 0.49 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -0.4 | Standard Deviation 0.61 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -1.3 | Standard Deviation 0.68 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -0.6 | Standard Deviation 0.73 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -1.6 | Standard Deviation 0.84 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -0.7 | Standard Deviation 0.72 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -1.7 | Standard Deviation 0.96 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -0.7 | Standard Deviation 0.82 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -1.9 | Standard Deviation 0.94 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -0.8 | Standard Deviation 0.78 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -1.9 | Standard Deviation 1.06 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -0.8 | Standard Deviation 0.79 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -1.8 | Standard Deviation 1.16 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Placebo | First injection, after 24 hours | 4.3 | Standard Deviation 0.96 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Nemolizumab 0.5 mg/kg | First injection, after 24 hours | 5.0 | Standard Deviation 1.20 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Placebo | First injection, after 48 hours | 4.0 | Standard Deviation 1.69 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Nemolizumab 0.5 mg/kg | First injection, after 48 hours | 5.3 | Standard Deviation 1.40 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=6